2023-04-18 07:48:12
AbClon (CEO Lee Jong-seo) disclosed some of the non-clinical and phase 1 clinical results of its CAR-T treatment ‘AT101 (development code name)’ at the American Association for Cancer Research (AACR).
Through this announcement, AbClon announced on the 18th that it confirmed complete remission in all patients in the medium-dose administration group in the phase 1 clinical trial of AT101.
First, the non-clinical results announced this time include the superiority and differentiation of AT101 in treating hematological cancer compared to existing CAR-T treatments. The company explained that AT101 suggested that AbClon’s independently developed h1218 antibody might have superior anticancer efficacy than all existing commercialized CAR-T products (Kymria, Yescata, etc.) that use FMC63 antibody equally. .
In particular, it was confirmed that AT101 acts effectively on CD19 mutant cells reported in patients who relapsed following CAR-T treatment. In addition, AT101 has several technological innovations that differentiate it from existing CAR-T treatments, such as △improvement of immunogenicity through humanized antibodies △unique drug efficacy enhancement mechanism △product production stability through automation in the manufacturing process.
Since the hematologic cancer CAR-T treatment is a one-time treatment, it is possible to confirm safety in the phase 1 clinical trial, determine the optimal dose for the phase 2 clinical trial, and immediately confirm the therapeutic effect on patients.
In this presentation on the results of the phase 1 clinical trial of AT101, AbClon disclosed the treatment effects of two groups, a low dose and a medium dose among three dose groups. In particular, in the case of the mid-dose administration group, AT101 was administered to 3 patients despite the lower dose compared to the global CAR-T treatments ‘Kymria’ and ‘Yescarta’, and complete remission was confirmed from all patients at the first checkup 4 weeks later. .
A company official said, “After confirming the complete remission of all patients in the medium dose group, both the clinical and development teams are inflated with anticipation for the birth of a CAR-T new drug.” , Partial remission was confirmed in 2 patients, and it proved an excellent effect compared to existing CAR-T treatments.”
1681804721
#AbClon #Complete #remission #hematological #cancer #patients #middle #dose #CART #phase #clinical #trial
